GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Eric Jonasch discussing a phase 1b/2 study of combination 177Lu girentuximab + cabozantinib and ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response in the region changes, researchers report. The detailed insights into cancer ...

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...